Read Time: 3 mins

Treating Drug-resistant Epilepsy – Why are we Waiting?

Copy Link
Published Online: Dec 4th 2015 European Neurological Review, 2015;10(2):171–5 DOI:
Authors: Paul Boon, Philippe Ryvlin, James W Wheless, Kensuke Kawai
Quick Links:
Article Information

Drug-resistant epilepsy (DRE) has been defined by the ad hoc Task Force of the International League Against Epilepsy (ILAE) Commission on Therapeutic Strategies as the failure of two appropriately chosen and tolerated anti-epileptic drugs (AEDs) (whether as monotherapy or in combination) to control seizures when used for an adequate period of time. The difference between the number of patients with DRE and the number of these patients who do not get access to adequate treatment is defined as the ‘treatment gap’, which is considered to be substantial. There are multiple possible causes that underlie the treatment gap in DRE: economic costs, natural history of epilepsy, deficiencies in health service provision, social stigma and other as yet unidentified causes. Factors affecting quality of life in DRE include depression and anxiety, raised risk of mortality and morbidity, increased healthcare utilisation and increased risk of adverse events with long- term use of AEDs, cognitive and memory impairment, seizure-related injuries, impaired ability to achieve educational and vocational goals, to drive, establish families and benefit from social relationships. Among the reasons for the greater risk of premature death are the raised risk of suicide in those patients with comorbid psychiatric disease and the increased incidence of sudden unexpected death among those with epilepsy. Managing epilepsy well involves more than just seizure reduction and when freedom from seizures cannot be achieved, addressing quality of life is likely to be more beneficial than interventions aimed at seizure reduction alone. Options exist for patients with DRE who are not candidates for epilepsy surgery, including dietary treatments, further attempts with AEDs and non-pharmacological interventions with devices. Further, non-invasive modalities are emerging, creating a more hopeful picture that the treatment gap for patients with DRE may be narrowed or even closed.


Drug-resistant epilepsy, vagus nerve stimulation, deep brain stimulation, epilepsy surgery, closed loop neurostimulation, AspireSR®


Epilepsy is one of the most common serious neurological conditions, has no geographic, social or racial boundaries and can affect people of all ages.1 It is frequently associated with co-morbidities, not just seizures, and is a condition that is linked with a high rate of premature death compared with that in the general population.1 The consensus proposal by the ad hoc Task Force of the International League Against Epilepsy (ILAE) Commission on Therapeutic Strategies defined drugresistant epilepsy (DRE) as the failure of two appropriately chosen and tolerated anti-epileptic drugs (AEDs) (whether as monotherapy or in combination) to control seizures when used for an adequate period of time.2,3 The ideal goal for treating newly diagnosed epilepsy is to eliminate seizures while having minimal side-effects; however, in DRE, the treatment goals are required to be more modest.2,4,5 These involve: optimizing long-term seizure control, maximising quality of life (QoL), minimising side effects, maximising adherence and decreasing seizure severity and the postictal period.

The consequences of DRE have significant QoL implications for patients. These include: depression and anxiety;5–7 raised risk of mortality and morbidity;6,8–10 increased healthcare utilisation;4,11,14 more adverse events (AEs) with long-term use of AEDs;5–7,13 cognitive and memory impairment;6,7,14 seizure-related injuries;6,7 and impaired ability to obtain educational and work goals; to drive; establish families; and develop and maintain social relations.7,13 Out of a population in Europe of 850 million people, a conservative estimate of people with active epilepsy is 6 million (prevalence of 8.2/1000).15 Of these 6 million people, epilepsy is well controlled with AEDs in 70 %.15 In the remaining 30 % with DRE, onequarter to one-third (450 000–600 000 people) are potential candidates for epilepsy surgery.15 Two-thirds to three-quarters of the people with DRE (approximately 1.4 million) are candidates for other therapies such as vagus nerve stimulation (VNS) Therapy, ketogenic diet, deep brain stimulation (DBS) or experimental AEDs. According to a recent survey of epilepsy clinicians who were asked about the DRE treatment gap, around 40 % of DRE patients have undergone a comprehensive evaluation and, of this 40 %, the proportion who had not received VNS Therapy or epilepsy surgery was 83 %.16

Risks Beyond Seizures
In addition to the risks associated with seizures (e.g. falls), there are risks linked with the underlying disease, neurobiological dysfunction, social stigma and AEs. These create a complex picture, for example, the risk of depression may be heightened by other risk factors such as AED-associated side effects and social stigma.17,18 Estimates for the prevalence of adults with depression in epilepsy range from 20 to 55 %.17,19–23 Furthermore, depression can increase the risk of drug resistance, surgical failure and treatment-related AEs.18,24 There may even be common neurobiological–pathogenic mechanisms between the two conditions so that epilepsy may promote depression and vice versa.25–27 Mood disorders are a possible side effect of AEDs28 and these are the main determinants of QoL in people with epilepsy.29

Memory decline and dysfunction also represent major concerns in patients with DRE. In a longitudinal study of 249 patients with temporal lobe epilepsy followed for 2–10 years, significant progressive memory decline occurred in 53 % of 102 of medically treated patients, in 60 % of 147 of surgically treated patients (primarily left hemisphere surgery). Memory decline was accelerated by unsuccessful surgery.30 Memory deficits can also be aggravated by a number of AEDs31 and, withdrawal of AEDs following epilepsy surgery has been shown to lead to improved intelligence quotient scores in children.32

Seizure-related injuries can be severe and even lethal. In a Canadian population-based study, patients with epilepsy appeared to have more domestic-related injuries, although sports-related injuries occurred in these patients less often for the unfortunate reason of them having fewer opportunities to participate in sport, which again impacts on their health.33 The biggest difference in comparison with the general population can be seen in terms of premature death with a four to eightfold higher risk of premature death.34,35

One of the reasons for the greater risk of premature death in people with epilepsy is the raised risk of suicide in those patients with comorbid psychiatric disease. This corresponds to an adjusted rate ratio (95 % confidence interval [CI]) of 9.86 (8.11–12.0; p<0.0001) in men and 23.6 (18.6–30.1; p<0.0001) in

women.36 Sudden unexplained death in epilepsy (SUDEP) is another main reason for premature death in people with epilepsy and is the second principal neurological cause in terms of years of potential life lost.37 The incidence of SUDEP in patients with epilepsy is approximately 1.16 per 1,000 (0.95–1.36).37 There appears, however, to be as much as 100-fold variation in the incidence of SUDEP between the various patients groups. SUDEP occurred with the highest incidence in studies of candidates for epilepsy surgery and epilepsy referral centres (2.2:1000–10:1000) and with the lowest incidence in children (0–0.2:1000).38 In a study of long-term mortality in childhood-onset epilepsy, 245 children (median age 3 years) were followed up for 40 years, nearly half of the subjects (51/107) who were not in 5-year terminal remission died (i.e., ≥5 years seizure-free at the time of death or last follow-up).39 Of the total 60 deaths, 33 (55 %) were related to epilepsy, including SUDEP in 18 subjects (30 %). New data including 34,000 patients aged 10–54 years (232,000 years of follow-up) indicate that VNS therapy is associated with a rate reduction in SUDEP. VNS therapy has also been associated with a significant improvement in QoL (see Table 1).40

Defining Treatment Success in Difficult-to-manage Epilepsy
Successful epilepsy surgery has been defined by several different endpoints in the literature.41–43 These include 1-, 2-, 5- and 10-year seizure freedom rates, withdrawal of all AEDs, acceptable side effects, return to education or work, improved QoL or mood and decreased healthcare utilisation. When a patient is not an epilepsy surgery candidate, suggested definitions of successful ongoing treatment might

include: fewer seizures (especially dangerous seizures), decreased rescue therapy use, good tolerability of treatment (long-term retention), QoL/mood improvements, lack of drug interactions, ease of use and good adherence to treatment. Concerns with the older medications include: prominent drug interactions (phenobarbital, phenytoin and carbamazepine); poor oral absorption in children (phenytoin and carbamazepine); long-term side effects such as an undesirable serum lipid profile (phenobarbital, phenytoin and carbamazepine); negative effects on bone heath (phenobarbital, phenytoin, carbamazepine and valproate) and teratogenic effects (phenobarbital, phenytoin, carbamazepine, valproate and topiramate).

Patient-rated tolerability is a major determinant of QoL.44 Tolerability as assessed by long-term retention rates for several AEDs and VNS therapy, are shown in Figure 1. VNS therapy has a long-standing association with enhanced QoL.40 Good adherence to treatment is equally critical and leads to a number of beneficial outcomes, such as improved seizure control,45–48 enhanced QoL,46 lower rate of seizurerelated job loss,46 hospitalisation and emergency department visits,4,45,49 lower fracture and motor vehicle accident rates45,46 and lower mortality rate in adults.45 VNS therapy has also been associated with reduced healthcare utilisation and costs (see Table 2).50,51

Mood is another factor in defining treatment success. Depression is a common co-morbidity in epilepsy52 and depressed mood is a predictor of poor subjective sleep quality and increased daytime sleepiness.53 Further, depressed mood and anxiety are correlated with increased rates of AED-associated AEs54,55 and these symptoms are also significant predictors of QoL.44

In summary, managing epilepsy well is about more than controlling seizures and this needs to be recognised in planning and delivering services.56 When seizure freedom cannot be achieved, addressing depressive comorbidity and reducing the burden of AED toxicity is likely to be far more beneficial than interventions aimed at reducing the frequency of seizure alone.57

Closing the Treatment Gap in Drug-resistant Epilepsy – A Japanese Success Story
There are multiple possible causes that underlie the treatment gap in DRE. Economic reason is only one of them.58 Some involve the natural history of the disease, for example, the asymptomatic phase of illness or the person’s own explanatory model or treatment-seeking behaviour (e.g. self-neglect). There may also be deficiencies in health service provision; social stigma, which discourages treatment seeking; and other causes that are, at present, unknown due to lack of research.

The treatment gap for DRE should be reduced by identifying the underlying causes and addressing each for each society. In Japan, for example, one of the major causes behind the treatment gap was under-recognition of the significance of palliative therapy for DRE and a specific medical system, in which approval and indication for a novel treatment was strictly controlled by the government, making VNS an so-called ‘orphan device’ in early 2000s. After epileptologists carried out extensive lectures and seminar series, aimed at not only physicians but general citizens and government audiences, which emphasised the significance of palliative treatment. VNS was approved in 2010 and uptake since has been rapid. Responder data from the VNS Japanese all-patient registry are promising. In 385 patients with mean age 24 (±14.8 years), which included 55 % with prior epilepsy surgery, the rates of responders with >50 % seizure reduction were 39.1 % (n=358), 46.6 % (n=356), 56.0 % (n=350) and 58.6 % (n=321) after 3, 6, 12 and 24 months of VNS, respectively. There were no severe complications, and most common AEs were cough (9.1 %) and voice change (9.6 %).

It is estimated that <1 % of Japanese patients with DRE receive VNS therapy. The treatment gap for DRE must be reduced by identifying the underlying causes and properly acting to address each cause. There is a large treatment gap in Asian countries that is disproportionately large considering its rapidly growing economy.

Drug-Resistant Epilepsy – Overview of Neuromodulation Treatment Options
Neurostimulation targets and modalities may be intracranial and extracranial; the former includes closed loop DBS and cortical stimulation or closed loop responsive neurostimulator system (RNS).59

Anterior nucleus thalamus-DBS has been investigated in the SANTE trial.60,61 One hundred and ten patients with medically refractory partial seizures from 17 US centres were randomised. A reduced seizure frequency with DBS treatment was observed compared with the control group, which was reduced further over time: 56 % at 2 years and 69 % at 5 years. Thirty-four per cent of patients experienced side effects of some sort. In another randomised controlled trial of responsive intracranial stimulation using cortical or intracranial electroencephalography (EEG) as a readout (n=240) in which one-third of the patients had undergone prior epilepsy surgery or VNS therapy, a 37 % seizure reduction was reported for those who had undergone DBS versus 17 % in controls.62,63 Also in this trial, seizure outcome improved after longer follow up (up to 6 years). No negative effects were noted in mood or cognition.

In a pilot study of 10 patients with epilepsy who received non-invasive VNS via auricular branch VNS three times a day for nine months, five out of the seven patients who completed the study experienced significant seizure reduction.64 The therapy was safe and well tolerated.

There is limited experimental evidence for non-invasive VNS, repetitive transcranial magnetic stimulation (rTMS) and trigeminal nerve stimulation (TNS).

There is preliminary evidence that trigeminal nerve stimulation, which is available via dermal application with a subcutaneous option, may be safe and effective in reducing seizures in patients with DRE.65,66 However, further investigation is needed before trigeminal nerve stimulation can be considered a recommendable approach.

A randomised, double-blind, sham-controlled trial was carried out in 21 patients, with malformations of cortical development and refractory epilepsy, who underwent five consecutive sessions of low-frequency rTMS.67 rTMS decreased significantly the number of seizures in the active group compared with the sham rTMS group (p<0.0001), and this effect lasted for at least 2 months. Further, preliminary cognitive evaluation suggested improvement in some aspects of cognition in the active rTMS group, although, again, validation of this approach in further studies is warranted.

There is also evidence that transcranial direct current stimulation reduces neuronal excitability68 and brings about a seizure reduction in animal models. Clinical studies conducted to date, however, have shown mixed results.69,70

The autostimulation feature of the latest AspireSR® VNS therapy device (Cyberonics, Inc., Houston, TX, US) works in a closed-loop modality, and is based on the premise that heart rate increases in over 80 % of all seizures.71 AspireSR senses heart beats and a cardiac-based seizure detection algorithm continuously analyses changes in relative heart rate. Stimulation is delivered when the heart rate increases above a programmable threshold. This algorithm was studied in Europe (E-36 study)72 and the US (E-37 study) and 51 patients admitted to the Epilepsy Monitoring Unit (EMU) for seizure and electrocardiogram (ECG) recording were evaluated during their EMU stay and followed-up over a long-term period. The primary endpoint of ≥80 % sensitivity for at least one algorithm setting was met with a very low false positive rate (maximum 7/hour). Significant improvements in clinical outcomes were achieved including seizure cessation, reduced seizure duration and severity and improved QoL.


  • DRE has a major negative impact and increases risks for patients.
  • While there is a clear definition of DRE there are often significant delays in identifying and evaluating patients with DRE.
  • There is a major treatment gap in patients with DRE that needs to be addressed (see Figure 2).
  • Mood, memory disturbances and seizure-related injuries adversely affect quality-of-life in patients with DRE. Addressing depressive comorbidity and reducing the burden of AED toxicity is likely to be far more beneficial than interventions aimed at reducing the frequency of seizure alone.
  • Several non-pharmacologic options (diet, devices) exist for patients with drug-resistant epilepsy who are not candidates for epilepsy surgery
  • Long-term retention rates are much higher for VNS compared with AEDs (see Figure 1), and seizure outcomes continue to improve over longer follow-up periods.
  • Closed-loop VNS is available and early data show great promise in reducing seizure burden and improved quality of life.

Article Information:

Paul Boon has received support from Cyberonics, Medtronic, Sorin and UCB for lecture and consultancy fees and for educational grants through his institution. Philippe Ryvlin have received speaker or consulting fees from Cyberonics, UCB Pharma and Eisai Pharmaceuticals. James W Wheless has received grants from NIH, Shainberg Foundation, Questcor, Novartis, GW Pharma and INSYS Inc. He has received a grant, is on the speaker’s bureau and is a consultant for Lundbeck. He is on the speaker’s bureau for Cyberonics. He is on the speaker’s bureau and is a consultant for Eisai and Supernus. He has received a grant from, and is a consultant for Upsher- Smith, and is a consultant for UCB. Kensuke Kawai has received lecture honorarium from Cyberonics, Nihon Koden, Otsuka Pharmaceutical, and GlaxoSmithKline.


Paul Boon, Sint-Pietersnieuwstraat 25, Ghent, B-9000, Belgium. E:


The publication of this article was supported by Cyberonics (Subsidiary of Livanova PLC). The views and opinions expressed are those of the authors and not
necessarily those of Cyberonics.


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.


Editorial assistance was provided by Catherine Amey at Touch Medical Media, London and funded by Cyberonics BVBA. This article reports the proceedings of a sponsored satellite symposium and as such has not been subject to the journal’s usual peer-review process




1. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540-6.
2. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
3. Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006;13(3):277-82.
4. Faught RE, Weiner JR, Guerin A, et al. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia. 2009;50(3):501-9.
5. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002;58(8 Suppl 5):S9-20.
6. Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res. 2002;50(1-2):21-32.
7. Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient’s perspective I. Descriptions and subjective perceptions. Epilepsy Res. 2000;41(1):39-51.
8. Lhatoo SD, Langan Y, Sander JW. Sudden unexpected death in epilepsy. Postgrad Med J. 1999;75(890):706-9.
9. Annegers JF, Coan SP, Hauser WA, et al. Epilepsy, vagal nerve stimulation by the NCP system, mortality, and sudden, unexpected, unexplained death. Epilepsia. 1998;39(2):206-12.
10. Van Ness PC. Therapy for the epilepsies. Arch Neurol. 2002;59(5):732-5.
11. Labiner DM, Paradis PE, Manjunath R, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology. 2010;74(20):1566-74.
12. Helmers SL, Paradis PE, Manjunath R, et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav. 2010;18(4):437-44.
13. Wheless JW. Intractable epilepsy: A survey of patients and caregivers. Epilepsy Behav. 2006;8(4):756-64.
14. Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology. 2002;58(8 Suppl 5):S21-6.
15. International Bureau for Epilepsy. EPILEPSY IN THE WHO EUROPEAN REGION: Fostering Epilepsy Care in Europe. EPILEPSY out of the Shadows. Available at: http://www. (Accessed 13 November 2015).
16. Data on file. Cybertronics Inc., Houston, TX, USA.
17. Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia. 1996;37(2):148-61.
18. Kanner AM. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders? Nat Clin Pract Neurol. 2009;5(3):132-3.
19. Lambert MV, Robertson MM. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia. 1999;40 Suppl 10:S21-47.
20. Indaco A, Carrieri PB, Nappi C, et al. Interictal depression in epilepsy. Epilepsy Res. 1992;12(1):45-50.
21. Baker GA, Jacoby A, Chadwick DW. The associations of psychopathology in epilepsy: a community study. Epilepsy Res. 1996;25(1):29-39.
22. Edeh J, Toone B. Relationship between interictal psychopathology and the type of epilepsy. Results of a survey in general practice. Br J Psychiatry. 1987;151:95-101.
23. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy. Significance and phenomenology. Arch Neurol 1986;43(8):766-70.
24. Hitiris N, Mohanraj R, Norrie J, et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007;75(2-3):192-6.
25. Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11(12):1093-102.
26. Catena-Dell’Osso M, Caserta A, Baroni S, et al. The relationship between epilepsy and depression: an update. Curr Med Chem. 2013;20(23):2861-7.
27. Epps SA, Weinshenker D. Rhythm and blues: animal models of epilepsy and depression comorbidity. Biochem Pharmacol 2013;85(2):135-46.
28. Cramer JA, Mintzer S, Wheless J, Mattson RH. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother. 2010;10(6):885-91.
29. Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006;5(5):399-405.
30. Helmstaedter C, Kurthen M, Lux S, et al. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol. 2003;54(4):425-32.
31. Levy RH. Antiepileptic Drugs. 5th edition ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2002.
32. Boshuisen K, van Schooneveld MM, Uiterwaal CS, et al. Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery. Ann Neurol 2015;78(1):104-14.
33. Tellez-Zenteno JF, Hunter G, Wiebe S. Injuries in people with self-reported epilepsy: a population-based study. Epilepsia. 2008;49(6):954-61.
34. Fazel S, Wolf A, Langstrom N, et al. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet. 2013;382(9905):1646-54.
35. Ding D, Wang W, Wu J, et al. Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurol. 2006;5(10):823-7.
36. Christensen J, Vestergaard M, Mortensen PB, et al. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007;6(8):693-8.
37. Thurman DJ, Hesdorffer DC, French JA. Sudden unexpected death in epilepsy: assessing the public health burden. Epilepsia. 2014;55(10):1479-85.
38. Tellez-Zenteno JF, Ronquillo LH, Wiebe S. Sudden unexpected death in epilepsy: evidence-based analysis of incidence and risk factors. Epilepsy Res. 2005;65(1-2):101-15.
39. Sillanpaa M, Shinnar S. Long-term mortality in childhoodonset epilepsy. N Engl J Med .2010;363(26):2522-9.
40. Ryvlin P, Gilliam FG, Nguyen DK, et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia. 2014;55(6):893-900.
41. Jobst BC, Cascino GD. Resective epilepsy surgery for drugresistant focal epilepsy: a review. JAMA. 2015;313(3):285-93.
42. Engel J, Jr., McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012;307(9):922-30.
43. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311-8.
44. Elsharkawy AE, Thorbecke R, Ebner A, May TW. Determinants of quality of life in patients with refractory focal epilepsy who were not eligible for surgery or who rejected surgery. Epilepsy Behav. 2012;24(2):249-55.
45. Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 2008;71(20):1572-8.
46. Hovinga CA, Asato MR, Manjunath R, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav. 2008;13(2):316-22.
47. Asato MR, Manjunath R, Sheth RD, CA, et al. Adolescent and caregiver experiences with epilepsy. J Child Neurol. 2009;24(5):562-71.
48. Modi AC, Rausch JR, Glauser TA. Early pediatric antiepileptic drug nonadherence is related to lower long-term seizure freedom. Neurology. 2014;82(8):671-3.
49. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49(3):446-54.
50. Helmers SL, Duh MS, Guerin A, et al. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol. 2012;16(5):449-58.
51. Helmers SL, Duh MS, Guerin A, et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav. 2011;22(2):370-5.
52. Kanner AM. The complex epilepsy patient: intricacies of assessment and treatment. Epilepsia. 2003;44 Suppl 5:3-8.
53. Moser D, Pablik E, Aull-Watschinger S, et al. Depressive symptoms predict the quality of sleep in patients with partial epilepsy--A combined retrospective and prospective study. Epilepsy Behav. 2015;47:104-10.
54. Gomez-Arias B, Crail-Melendez D, Lopez-Zapata R, Martinez- Juarez IE. Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs. Seizure. 2012;21(8):588-94.
55. Panelli RJ, Kilpatrick C, Moore SM, et al. The Liverpool Adverse Events Profile: relation to AED use and mood. Epilepsia. 2007;48(3):456-63.
56. Mula M, Cock HR. More than seizures: improving the lives of people with refractory epilepsy. Eur J Neurol 2015;22(1):24-30.
57. Luoni C, Bisulli F, Canevini MP, et al. Determinants of healthrelated quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52(12):2181-91.
58. Kale R. Global Campaign Against Epilepsy:the treatment gap. Epilepsia. 2002;43 Suppl 6:31-3.
59. Vonck K, Boon P. Epilepsy: closing the loop for patients with epilepsy. Nat Rev Neurol. 2015;11(5):252-4.
60. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51(5):899-908.
61. Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology. 2015;84(10):1017-25.
62. Sun FT, Morrell MJ, Wharen RE, Jr. Responsive cortical stimulation for the treatment of epilepsy. Neurotherapeutics. 2008;5(1):68-74.
63. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology. 2015;84(8):810-7.
64. Stefan H, Kreiselmeyer G, Kerling F, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia. 2012;53(7):e115-8.
65. DeGiorgio CM, Soss J, Cook IA, et al. Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy. Neurology. 2013;80(9):786-91.
66. DeGiorgio CM, Murray D, Markovic D, Whitehurst T. Trigeminal nerve stimulation for epilepsy: long-term feasibility and efficacy. Neurology. 2009;72(10):936-8.
67. Fregni F, Otachi PT, Do Valle A, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in patients with refractory epilepsy. Ann Neurol. 2006;60(4):447-55.
68. Nitsche MA, Paulus W. Transcranial direct current stimulation-- update 2011. Restor Neurol Neurosci. 2011;29(6):463-92.
69. Varga ET, Terney D, Atkins MD, et al. Transcranial direct current stimulation in refractory continuous spikes and waves during slow sleep: a controlled study. Epilepsy Res. 2011;97(1-2):142-5.
70. Auvichayapat N, Rotenberg A, Gersner R, et al. Transcranial direct current stimulation for treatment of refractory childhood focal epilepsy. Brain Stimul. 2013;6(4):696-700.
71. Leutmezer F, Schernthaner C, Lurger S, et al. Electrocardiographic changes at the onset of epileptic seizures. Epilepsia. 2003;44(3):348-54.
72. Boon P, Vonck K, van Rijckevorsel K, et al. A prospective, multicenter study of cardiac-based seizure detection to activate vagus nerve stimulation. Seizure. 2015;32:52-61
73. Novy J, Bartolini E, Bell GS, et al. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epilepsy Res. 2013;106(1-2):250-6.
74. Catarino CB, Bartolini E, Bell GS, et al. The long-term retention of zonisamide in a large cohort of people with epilepsy at a tertiary referral centre. Epilepsy Res. 2011;96(1-2):39-44.
75. Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia. 2000;41(12):1592-6.
76. Depondt C, Yuen AW, Bell GS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006;77(1):101-3..

Further Resources

Share this Article
Related Content In Epilepsy
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72